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Abstract: Introduction: Evaluation of pancreatic ductal adenocarcinoma (PDAC) after
chemoradiotherapy downstaging is challenging due to computed tomography (CT) overestimation
of tumor extension and residual vascular involvement, limiting access to surgery to some patients
with potentially resectable tumors. With this study, we wanted to assess which radiological findings
are most reliable at pre-operative imaging in the evaluation of PDAC after chemoradiotherapy
in order to achieve complete resection. Methods: We retrospectively enrolled 71 patients with
locally advanced and borderline resectable PDAC who underwent neoadjuvant chemoradiotherapy.
Pre-operative CT or magnetic resonance (MR) have been evaluated by three radiologists to assess
major qualitative and quantitative parameters of lesions. Accuracy, sensitivity, and specificity
compared to anatomopathological results were evaluated for each parameter. Cohen’s K-coefficient
has been calculated to evaluate the inter-observer agreement (IOA). Both single and consensus lecture
have been tested. Different dimensional cut-offs were tested to categorize tumors according to
their major axis and to compare with anatomopathological diameter, tumor persistence, and margin
infiltration. Results: A 25 mm cut-off was 67% sensitive, 90% specific, and 77% accurate in assessing
real tumor dimension. 25 mm cut-off reported a 64% sensitivity, 78% specificity, and 69% accuracy
in assessing R0 resection. Each 5 mm increment of major axis dimension there is an odds ratio (OR)
1.79 (95% CI 1.13–2.80, p = 0.012) for R+ resection. Imaging presence of the perivascular cuff is not
associated with tumor persistence and resection margin infiltration (p = 0.362). Lesion enhancement
and pattern homogeneity were not accurate in determining tumor persistence. IOA was generally
poor to fair, except for >25 mm cut-off classification where IOA was moderate. Diagnostic accuracy
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is superior in consensus lecture rather than single lecture. Conclusion: Imaging methods tend to
underestimate PDAC resectability after neoadjuvant-CRT. IOA is poor to fair in evaluating most of the
qualitative parameters of downstaged pancreatic adenocarcinoma. Surgery should be considered for
downstaged borderline resectable PDACs, independently from perivascular cuff presence, especially
for tumors smaller than 25 mm.
Keywords: pancreas; pancreatic cancer; adenocarcinoma; downstaging; CT; chemotherapy
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) represents one of the most common causes of
cancer-related death in the United States and Europe, with a life expectancy of about 5% at 5 years [1,2].
In fact, PDAC usually presents in an advanced stage of disease at diagnosis with diffuse involvement
of major vessels and growth beyond pancreatic borders or metastases, which makes only 20% of cases
primarily resectable [3]. Among unresectable PDAC, 70% presents already in stage IV at diagnosis
and then can only benefit from palliation [4]; however, 30% of unresectable PDAC includes locally
advanced and borderline resectable cancers, which after successful neoadjuvant chemoradiotherapy
(CRT) downstaging can be suitable for radical resection (R0), which remains the only curative
therapeutic option in order to avoid local recurrence [5,6]. Morbidity and survival of R0 resection after
neoadjuvant CRT is similar to patients R0 resectable at diagnosis [7], with approximately one-third of
initially non-resectable tumors became resectable after neoadjuvant CRT [8–10]. Neoadjuvant CRT
is then indicated in doubtful cases or when the R1 resection risk is high [2]. The main advantages of
neoadjuvant CRT are to achieve local tumor reduction, early identification of patients with rapidly
progressive disease, and to grant access to chemotherapy in the event that an adjuvant one could
not be administered in the post-surgical phase [11]. Considering the great variability of the studies
in terms of CRT protocol and patient selection, is not clear in literature what proportion of patients
become effectively resectable after downstaging therapy [12]. Actually, radiological assessment of
residual PDAC after neoadjuvant CRT represents one of the major radiological challenges in pancreatic
cancer management [12]. It has long been known that computed tomography (CT), despite being
the method of choice for the staging of PDAC, tends to be less accurate in the evaluation of the
effective post-CRT resectability, reporting an overestimation of real tumor extension in most of the
studies [13–15]. The mismatch between radiological and histological response in the downstaging
assessment is mainly due to the anatomopathological nature of PDAC, which consists of a great
number of tumor cells embedded in a dense fibrotic stroma. After CRT, tumor cell numbers may be
reduced, but the preexisting fibrous matrix persists, with the eventual addition of further fibrosis
and a variable quote of perilesional edema, mimicking pathologic tumor tissue persistence [16].
Even inflammatory remodeling following bile duct drainage can compromise the downstaging
assessment [12]. With this paper, we attempt to identify the most reliable imaging parameters in our
multi-center population for the correct evaluation of the PDAC downstaged after neoadjuvant CRT,
in particular regarding the most common qualitative and quantitative imaging criteria in comparison
with the anatomopathological specimen.
2. Methods
2.1. Patients Population
We retrospectively enrolled patients between February 2013 and July 2017 with a diagnosis of
borderline resectable or locally advanced PDAC in agreement with Society of Abdominal Radiology
and American Pancreatic Association criteria [17] after the end of their downstaging therapy with
neoadjuvant CRT. Patients were selected from the revision of radiological, oncological, surgical, and
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anatomopathological databases of the Pancreas Institute from Policlinico “G.B. Rossi” of Verona,
“Sacro Cuore—Don Calabria” Hospital of Negrar, and “P. Pederzoli” Hospital of Peschiera del Garda.
The inclusion criteria were: patient underwent radical surgery after response to neoadjuvant CRT;
availability of the anatomopathological specimen; availability of a contrast-enhanced CT or magnetic
resonance (MR) performed between the end of neoadjuvant CRT and within 3 months before surgery.
2.2. Imaging Technique
CT was performed by using two multi-slice equipment 64-detector rows (Brilliance 64; Philips
Healthcare, Best, The Netherlands. Perspective 64; Siemens Healthcare, Erlangen, Germany). Scans
were acquired before and after 1.5 mL/kg intravenous injection of iodine contrast media (Ultravist
370, Schering, Berlin, Germany) during pancreatic arterial phase (15s after aortic bolus-tracking peak),
venous phase (60–70s), and equilibrium phase (5 min). Section thickness was 2 mm, kV 120, and
mAs 125–250. MR was performed by using a 1.5T equipment (Avanto, Siemens Healthcare, Erlangen,
Germany), including the following pulse sequences: axial fat-suppressed T1-weighted gradient-echo;
axial/coronal T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE); axial
fat-suppressed T2-weighted turbo spin-echo; single shot HASTE MR cholangiopancreatography.
Diffusion-weighted images were acquired using echo-planar imaging sequences with three b-values
(50, 400, 800 s/mm2). Dynamic imaging was performed with a volumetric 3D gradient-echo pulse
sequence (volume interpolated breath-hold examination) with fat saturation on the axial plane, during
injection of 0.2 mL/kg of Gd-BOPTA (MultiHance, Bracco, Milan, Italy) with the same phases described
for CT evaluation.
2.3. Imaging and Anatomopathological Evaluation
Imaging parameters have been evaluated by three radiologists: one radiologist with more than
18 years’ experience in pancreatic imaging, one middle-expert general radiologist from a different
institute, and one young radiologist who trained in our pancreatic high-volume center. Quantitative
parameters evaluated were: tumor dimensions in the three common orthogonal axes; tumor major
axis; tumor volume. Main qualitative parameters evaluated were: tumor location; tumor enhancement
compared to pancreatic parenchyma in arterial, venous, and equilibrium phases; enhancement
homogeneity; tumor persistence (hypovascular non-fibrous tissue inside the lesion); fibrosis presence;
main pancreatic duct dilatation >5 mm; retroperitoneal infiltration; involvement of portal vein, celiac
trunk, mesenteric artery, mesenteric vein; perivascular cuff (hypodense avascular undefined tissue
around celiac trunk and major vessels). Tumor dimensions, persistence, fibrosis, retroperitoneal
infiltration, and presence of surgical margin infiltration (R+) have been subsequently evaluated on the
operative sample by an expert pathologist with decades of experience in pancreatic tumors.
2.4. Statistical Analysis
Imaging and anatomopathological parameters were categorized into dichotomous classes.
Different dimensional cut-offs were considered with an increase of 5 mm to categorize the tumors
according to their major axis. Single radiological evaluations and consensus evaluation have been
tested. Consensus evaluation was considered as the most frequent measure among the three single
evaluations of the same parameter for qualitative measures and as the mean value for quantitative
measures. The single evaluation from pancreas-master radiologist was taken as the imaging gold
standard and compared to consensus evaluation. Accuracy, sensitivity, and specificity compared to
anatomopathological results were evaluated for each parameter. Chi-Square test was used to assess
correlations between categorical variables. A logistic regression model was used to calculate the
risk of R+ resection related to the dimensions at imaging. Cohen’s K-coefficient has been calculated
between single evaluations to assess the inter-observer agreement (IOA). Continue variables with
normal distribution were expressed as mean ± standard deviation, while median (interquartile range)
was used for non-normal distributions. Statistical analysis was performed by using Analyse-it software
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for Microsoft Excel (Analyse-it Software, version 4.51, Ltd, http://www.analyse-it.com/; 2009) and
IBM SPSS Statistic (v.19).
3. Results
3.1. Population and Tumour Characteristics
In total, 71 patients met the inclusion criteria and have been included in the study. All major
population characteristics are summarized in Table 1. The mean age of patients was 63.8± 8.4 years and
45.1% were males. Further, 78.9% of patients have been studied with CT, 21.1% with MR, while 45.1% of
patients received FOLFIRINOX CRT, 32.4% Gemcitabine-Abraxane, 2.8% FOLFIRINOX-radiotherapy,
2.8% Gemcitabine-Abraxane-radiotherapy, and 16.9% received a combination of previous mentioned
chemotherapeutic agents. Additionally, 78.9% of patients underwent duodenocephalopancreatectomy,
15.5% splenopancreatectomy, and 5.6% total pancreatectomy.
Table 1. Main characteristics of the study population.
Study Population (N = 71) Values
Age (years) 63.8 ± 8.4
Male (%) 45.1
CT evaluation (%) 78.9
MR evaluation (%) 21.1
FOLFIRINOX (%) 45.1
Gemcitabine-Abraxane (%) 32.4
Other CRT protocol (%) 22.5
Dudoenocephalopancreatectomy (%) 78.9
All major findings from imaging and anatomopathological evaluation are summarized in Table 2.
At the consensus evaluation, 97.7% of lesions were >15 mm cut-off, 81.8% were >20 mm, 40.9% were
>25 mm, and 20.5 were >30 mm. Median major axis dimension was 22.3 (18.7–27) mm at consensus
evaluation compared to 23.5 (15–30) mm at anatomopathological observation. The majority of lesions
were located in the head-isthmus of the pancreas and in the uncinate process, both at imaging and
histology. The strong minority of the lesions showed positive enhancement compared to the healthy
pancreatic parenchyma, both at the single and consensus assessment. Significant discrepancies were
reported in the evaluation of the homogeneity pattern in the three contrast-enhanced phases between
the single and the consensus evaluation. Most lesions showed fibrosis both at imaging and at pathology
observation. The perivascular cuff was present in about one-third of imaging evaluations. Tumor
persistence was shown in half of the cases at the imaging evaluation and then turned out to be much
more frequent in the surgical specimen. Surgical resection margins were mostly infiltrated at the
post-operative evaluation, with 62% of R1 and only one patient with R2 resection, although more than
half of the cases did not demonstrate retroperitoneal involvement.
Table 2. Characteristics of lesions at PER single evaluation and consensus evaluation, compared to the
anatomopathological findings. PER = Pancreas Expert Radiologist. AP = Anatomopathology.
Lesion Parameters (N = 71) PER Consensus AP
Major Axis (mm) 25 (20–30) 22.3 (18.7–27) 23.5 (15–30)
Arterial 28.5 65.1 −
Venous 88.3 50 −Homogeneous Pattern (%)
Equilibrium 26.5 58.8 −
Venous 4.8 1.59 −
Enhancement (%) Equilibrium 21.9 9.4 −
Perivascular Cuff (%) 36.6 26.8 −
Tumor Persistence (%) 49.3 47.9 78.9
Retroperitoneal Infiltration (%) 43.7 29.6 23.9
Fibrosis (%) 64.1 71.8 57.8
R+ Resection (%) − − 63.4
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3.2. Imaging and Anatomopathological Correlation
There were no significant differences in sensitivity, specificity, and accuracy between the single
pancreatic-expert radiologist and consensus lecture, although there was always a slight tendency for
consensus reading to be more accurate. Sensitivity and accuracy in evaluating real tumor dimensions
progressively decreased with the increment of the dimensional cut-off.
The reported accuracy values for the imaging consensus evaluation of fibrosis were 64%, 62%
for tumor persistence (Figure 1), and 64% for retroperitoneal involvement. All sensitivity, specificity,
and accuracy values reported for imaging parameters referring to the respective anatomopathological
findings are summarized in Table 3.
Cancers 2019, 11, x FOR PEER REVIEW 6 of 11 
When measured by a pancreatic expert radiologist, each 5 mm increase in tumor dimension 
reported an OR of 1.79 (95% CI 1.13–2.80, p = 0.012) for R+ resection, with an of OR 6.56 (95% CI 
2.07–20.81, p = 0.001) when bigger than 25 mm. Even at consensus evaluation, lesions >25 mm 
reported an OR of 3.39 (95% CI 1–11.58, p = 0.05) for a R+ resection. 
Table 4. Sensitivity, specificity, and accuracy values reported for 25 mm cut-off in reference to the 
anatomopathological margin infiltration and tumor persistence. AC = Accuracy. SE = Sensitivity. SP 
= Specificity. 
25 mm vs. SE (%) SP (%) AC (%) 
Surgical margin i filtration (R+) 64 78 69 
Retroperitoneal inf ltration 23 94 58 
Tumor P rsistence 51 67 53 
Figure 1. CT images of PDAC (pancreatic phase). At the CT evaluation; the lesion before 
chemoradiotherapy (left) is quite similar to the post-chemoradiotherapy evaluation (right), showing 
only minimal dimensional regression. No tumor persistence was reported in the resection specimen. 
The presence of the perivascular cuff at imaging (Figure 2) evaluation reported a 30% accuracy 
in determining tumor persistence and retroperitoneal margin infiltration in the 
anatomopathological specimen. No statistical correlation was reported between the presence of the 
perivascular cuff and R+ resection, both at pancreatic-expert evaluation (p = 0.362) and consensus (p 
= 0.098). Whereas tumor density homogeneity in venous and equilibrium phase reported an 
accuracy of 50% and 63% respectively in evaluating tumor persistence, tumor enhancement in both 
phases was not an accurate parameter (19% and 28%, respectively). However, the presence of 
enhancement in the venous and equilibrium phase was found to be an accurate measure of the 
presence of fibrosis, with respective accuracy of 95% and 89% in consensus lecture. 
Figure 1. CT images of PDAC (pancreatic phase). At the CT evaluation; the lesion before
chemoradiotherapy (left) is quite similar to the post-chemoradiother py evaluation (right), showing
only minimal dim nsional regression. No tumor persistence was reported in the resec ion specimen.
Table 3. Sensitivity, specificity, and accuracy values reported for imaging parameters referring to the
respective anatomopathological finding. AC = Accuracy. SE = Sensitivity. SP = Specificity.
Lesion Parameters (N = 71) SE (%) SP (%) AC (%)
>20 mm 93 46 79
>25 mm 67 90 77Major Axi
>30 mm 31 86 66
Retroperitoneal infiltration 53 68 64
Fibrosis 50 65 64
Tumor Persistence 64 57 62
The surgical resection margin R classification was statistically correlated to the size of the
lesion when categorized above or below the 25 mm cut-off at imaging, both when measured by
the pancreatic-expert radiologist (p = 0.001) and at consensus evaluation (p = 0.037). In total, 78% of
lesions with R0 resections were <25 mm at pancreatic-expert radiologist evaluation, while 65% of R1
resections were >25 mm. Only 14% of tumors >25mm at imaging led to an R0 resection.
The 25 mm cut-off was 67% sensitive, 90% specific, and 77% accurate in assessing real tumor
dimensions. The 25 mm cut-off was the only one capable of reaching values of accuracy >50% in
assessing tumor persistence (53%), retroperitoneal infiltration (58%), and surgical margin infiltration
(69%). Referring to R+ surgical margin infiltration, the 25 mm cut-off was 64% sensitive and 78%
specific. Moreover, sensitivity and specificity for 25 mm cut-off were, respectively, 23% and 94% related
to retroperitoneal infiltration, and 51% and 67% related to tumor persistence (Table 4).
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Table 4. Sensitivity, specificity, and accuracy values reported for 25 mm cut-off in reference to the
anatomopathological margin infiltration and tumor persistence. AC = Accuracy. SE = Sensitivity.
SP = Specificity.
25 mm vs. SE (%) SP (%) AC (%)
Surgical margin infiltration (R+) 64 78 69
Retroperitoneal infiltration 23 94 58
Tumor Persistence 51 67 53
When measured by a pancreatic expert radiologist, each 5 mm increase in tumor dimension
reported an OR of 1.79 (95% CI 1.13–2.80, p = 0.012) for R+ resection, with an of OR 6.56 (95% CI
2.07–20.81, p = 0.001) when bigger than 25 mm. Even at consensus evaluation, lesions >25 mm reported
an OR of 3.39 (95% CI 1–11.58, p = 0.05) for a R+ resection.
The presence of the perivascular cuff at imaging (Figure 2) evaluation reported a 30% accuracy
in determining tumor persistence and retroperitoneal margin infiltration in the anatomopathological
specimen. No statistical correlation was reported between the presence of the perivascular cuff and
R+ resection, both at pancreatic-expert evaluation (p = 0.362) and consensus (p = 0.098). Whereas
tumor density homogeneity in venous and equilibrium phase reported an accuracy of 50% and 63%
respectively in evaluating tumor persistence, tumor enhancement in both phases was not an accurate
parameter (19% and 28%, respectively). However, the presence of enhancement in the venous and
equilibrium phase was found to be an accurate measure of the presence of fibrosis, with respective
accuracy of 95% and 89% in consensus lecture.Cance s 2019, 11, x FOR PEER REVIEW 7 of 11 
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Figure 2. CT examination (pancreatic phase) of ductal adenocarcinoma of the pancreatic head with the
presence of the perivascular cuff surrounding the superior mesenteric artery.
3.3. Interobserver Agreement
Concordance values between the three radiologists are summarized in Table 5. For dimensional
assessment, the concordance between individual evaluations has progressively increased from poor
to oderate with the increment of the dimensional cut-off. IOA was always poor in assessing the
enhancement of lesions and its homogeneity after the administration of contrast media. The evaluation
of fibrosis presence and retroperitoneal involvement was poor to fair too. The concordance in assessing
the tumor persistence was fair to moderate. Most of the time IOA was higher between the pancreas
expert and young radiologist than between the pancreas expert and general radiologist coming from a
different institute. Good IOA was reported between the pancreatic expert radiologist and consensus
evaluation regarding 25 mm cut-off (k = 0.61) and perivascular cuff presence (k = 0.69).
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Table 5. IOA (Cohens’ k coefficient) among the three radiologists in the evaluation of single imaging
parameters. IOA = Interobserver Agreement. PER = Pancreatic Expert Radiologist. GR = Middle-expert
General Radiologist. YR = Young Radiologist.
Parameters PER vs. GR (k) PER vs. YR (k) GR vs. YR (k)
>15 mm −0.03 0.31 −0.07
>20 mm 0.18 0.39 0.32
>25 mm 0.33 0.55 0.46Major Axis
>30 mm 0.48 0.53 0.54
Homogeneous pattern
Arterial −0.03 0.17 0.24
Venous 0.08 0.08 0.02
Equilibrium 0.09 0.24 0.18
Venous −0.03 −0.04 −0.04
Enhancement Equilibrium −0.09 −0.29 0.21
Retroperitoneal infiltration −0.03 0.28 0.39
Fibrosis 0.28 −0.11 0.27
Perivascular Cuff 0.29 0.59 0.46
Tumor Persistence 0.28 0.48 0.38
4. Discussion
Imaging is of fundamental importance in the identification, characterization, and staging of
PDAC. One of the biggest challenges in pancreatic imaging is to correctly restage a locally advanced
PDAC after downstaging CRT to assess its resectability. In 2001, White et al. [14] first noticed how
CT tends to overestimate the extension of a locally advanced PDAC subjected to neoadjuvant-CRT.
The overestimation is due to multiple factors, in particular to the presence of peripancreatic edema
and fibrosis induced by CRT, which can mimic a residual tumor. In 2009, Kim et al. [18] confirmed
how neoadjuvant CRT decreases the accuracy of PDAC restaging, however, not enough to affect its
resectability. Soon after, Morgan et al. [19] showed how patients who underwent neoadjuvant-CRT and
were judged to be resectable at imaging reported higher overall survival than unresectable patients
and resectable patients not treated with CRT. Therefore, they stressed that it was essential to achieve
high values of accuracy on the determination of resectability post-CRT, suggesting not to overestimate
the vascular involvement in order not to deny surgery to potentially resectable patients. In their
study it also emerged that in patients undergoing CRT, the IOA drastically dropped in staging and
in the determination of resectability compared to patients not treated with CRT. They suggested that
probably the reader’s knowledge of whether the patient underwent CRT or not which could be a bias
for resectability determination, a finding supported by the fact that the resectable patients were more in
the CRT group than in the control. In our study, every patient underwent neoadjuvant-CRT according
to inclusion criteria, so we can confirm that IOA in evaluating tumor characteristics is generally poor
to fair in those patients. Pre-CRT CT or MR was not considered in our study. If, on the one hand, the
comparison with the previous CT can be helpful, there is the risk of provoking a misleading enthusiasm
in the reader, affecting its determination of resectability. For example, a dimensional reduction of a
lesion does not essentially mean its resectability and needs to be considered separately. In fact, as
shown by Cassinotto et al. [20], changes in tumor major diameter are not always associated with R0
resection. Moreover, Katz et al. [21] demonstrated that current radiological measures of CRT response,
such as Response Evaluation Criteria In Solid Tumor (RECIST) [22], are not reliable in evaluating
effective resectability of PDAC. To blind the radiologist on the neoadjuvant-CRT carried out or on the
previous CT or MR study in order to avoid misleading evaluations in our opinion is not appropriate
in clinical practice, but should be useful to research what are the most common factors not to be
overestimated at preoperative imaging to ensure greater accuracy and a good IOA on the judgment of
resectability. In the setting of this study, we wanted to consider only patients subjected to CRT in order
to better understand which parameters are the most reliable in the evaluation of this type of patient.
Moreover, pre-downstaging imaging, and therefore tumor shrinkage, was not considered in order not
to influence readers on the actual tumor size.
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Probably one of the most misleading causes of underestimation of PDAC resectability is the
persistence of perivascular hypodense tissue after neoadjuvant-CRT. This perivascular cuff could better
rely on lymphatic congestion or CRT-related fibrotic rehash than on tumor infiltration. Indeed, in our
study the presence of the perivascular cuff was not accurate in assessing tumor persistence and was
not statistically correlated with surgical margin infiltration and R+ resection (p = 0.362), therefore we
suggest giving it little consideration in resectability evaluation. In the same way, as proven by Cassinotto
et al. [13], some degrees of portal and superior mesenteric vein strain and stenosis could persist after
CRT due to fibrotic tissue, but do not necessarily mean that tumor is still infiltrating the vessels.
Despite the homogeneity of tumor density in the venous and equilibrium phase being quite
accurate in evaluating tumor persistence, it was not useful in assessing its resectability in our study.
Our finding confirms that one should not rely on tumor density and enhancement to predict R0
resections, because imaging cannot effectively differentiate tumor from necrotic or fibroinflammatory
tissue post-neoadjuvant CRT [20].
More than half of our patients presented margin infiltration at histological evaluation of surgical
specimen, probably due to a high component of borderline resectable PDAC in our population.
However, the near totality of the R+ was R1, and therefore reported a solely microscopic surgical
margin infiltration. For this reason, we could always consider the size and the extent at the
anatomopathological evaluation coinciding with the real measurements of the tumors. In our study, the
strong majority of R0 tumors were smaller than 25 mm, while about half of R+ tumors were >25 mm,
with a significant statistical difference both at pancreatic expert radiologist (p = 0.001) and consensus
evaluation (p = 0.037). Testing different major axis cut-offs, we found that there is no one capable of
simultaneously maximizing sensitivity, specificity, and accuracy referring to anatomopathological
tumor diameter, persistence, and retroperitoneal margin infiltration. Nevertheless, we found how
25 mm imaging cut-off is accurate in assessing real tumor dimension, reporting moderate IOA.
Referring to retroperitoneal infiltration, 25 mm imaging cut-off is 94% specific, 58% accurate, but only
23% sensitive. However, when considering overall surgical margin infiltration, the 25 mm cut-off
was 64% sensitive, 78% specific, and 69% accurate in predicting an R+ resection. These mean that
about 70% of the times, the 25 mm cut-off can correctly diagnose the R0 or R+ of the surgical resection.
In particular, if tumor dimensions are evaluated by an expert radiologist, each increase of 5 mm leads
to a 79% increase in R+ risk (p = 0.001), reporting a higher risk for tumors >25 mm with an OR of 6.56
(95% CI 2.07–20.81, p = 0.001).
All these findings support the argument to be more aggressive in borderline resectable PDAC
multimodality treatment, as previously suggested in literature, in order to not deny surgery
to a potentially resectable patient [19–21]. In our multi-center experience, common criteria of
tumor resectability cannot be fully applicable to PDAC after neoadjuvant chemotherapy, due to
overestimation of tumor extension by imaging studies. We suggest using a multiparametric approach
to resectability evaluation after CRT. In particular, surgery must be considered for tumors which after
CRT are smaller than 25 mm, with reduction of vascular contact, independently from the persistence
of the perivascular cuff or inhomogeneous enhancement.
A final interesting fact is that IOA mostly tended to be higher between the pancreas expert
and young radiologist who did all their residency period in a pancreatic institute, than between the
pancreas expert and general older radiologist coming from a different non-specialized institute. Most
of the time the pancreatic expert radiologist agreed with young radiologist but disagreed with the
older general radiologist. For this reason, consensus evaluation often coincided with the expert’s
evaluation and preserves diagnostic and statistical significance. This underlines how radiological
specific expertise is essential in a highly specific ambit, such as pancreatic diseases, and more important
than years of working experience and is independent from overall radiological knowledge.
The retrospective setting was the main limitation of the study. The moderately low number of
patients who were included in the analyzes may represent an additional limitation. Further prospective
studies on larger series are needed in the future to confirm the findings in this study. Furthermore,
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comparison studies between downstaging and upfront resection will be useful in the future, eventually
considering preoperative imaging and tumor shrinkage.
5. Conclusions
Common radiological criteria are not fully applicable to assess resectability of PDAC after CRT.
Basically, imaging methods tend to underestimate PDAC resectability after neoadjuvant-CRT. IOA is
poor to fair in evaluating most of the qualitative parameters of downstaged pancreatic adenocarcinoma.
Surgery should be considered for downstaged borderline resectable PDACs, independently from
perivascular cuff presence, especially for tumors smaller than 25 mm.
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Abbreviations
CT Computed Tomography
CRT Chemoradiotherapy
HASTE Half-Fourier Acquisition Single-shot Turbo spin-Echo
IOA Inter-Observer Agreement
MR Magnetic Resonance
OR Odds Ratio
PDAC Pancreatic Ductal Adenocarcinoma
R0 No Surgical Margin Infiltration
R+ Positive Surgical Margin Infiltration
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